Phase	B-study_type
II	I-study_type
study	I-study_type
of	O
R	O
-	O
CVP	O
followed	O
by	O
rituximab	B-arm_description
maintenance	I-arm_description
therapy	I-arm_description
for	O
patients	O
with	O
advanced	O
marginal	O
zone	O
lymphoma	O
:	O
consortium	O
for	O
improving	O
survival	O
of	O
lymphoma	O
(	O
CISL	O
)	O
study	O
Phase	B-study_type
II	I-study_type
study	I-study_type
of	O
R	O
-	O
CVP	O
followed	O
by	O
rituximab	B-arm_description
maintenance	I-arm_description
therapy	I-arm_description
for	O
patients	O
with	O
advanced	O
marginal	O
zone	O
lymphoma	O
:	O
consortium	O
for	O
improving	O
survival	O
of	O
lymphoma	O
(	O
CISL	O
)	O
study	O
SungYongOh	B-authors

0000	O
-	O
0002	O
-	O
8321	O
-	O
4113	O
JinSeokKim	B-authors
SeokJinKim	B-authors
DokHyunYoon	B-authors
Deok	B-authors
-	I-authors
HwanYang	I-authors
WonSikLee	B-authors
HyoJungKim	B-authors
Ho	B-authors
-	I-authors
YoungYhim	I-authors
SeongHyunJeong	B-authors
JongHo	B-authors
Won	I-authors
SueeLee	B-authors
HyunJee	B-authors
Kong	I-authors
Sung	B-authors
-	I-authors
NamLim	I-authors
JunHo	B-authors
Ji13	I-authors
KyungAKwon	B-authors
Gyeong	B-authors
-	I-authors
WonLee	I-authors
JaeHoonLee	B-authors
SupHo	B-authors
Lee	I-authors
Ho	B-authors
-	I-authors
JinShin	I-authors
CheolwonSuh	B-authors
csuh@amc.seoul.kr	O

Songpa	O
-	O
gu	O
,	O
Seoul	O
05505	O
,	O
Republic	O
of	O
Korea	O
Busan	O
49201	O
,	O
Republic	O
of	O
Korea	O
.	O
Seoul	O
06351	O
,	O
Republic	O
of	O
Korea	O
.	O
Seoul	O
03722	O
,	O
Republic	O
of	O
Korea	O
.	O
Songpa	O
-	O
gu	O
,	O
Seoul	O
05505	O
,	O
Republic	O
of	O
Korea	O
.	O
Hwasun	O
58128	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
04511	O
,	O
Republic	O
of	O
Korea	O
.	O
Anyang	O
14068	O
,	O
Republic	O
of	O
Korea	O
.	O
Jeonju	O
54907	O
,	O
Republic	O
of	O
Korea	O
.	O
Suwon	O
16499	O
,	O
Republic	O
of	O
Korea	O
.	O
Seoul	O
04401	O
,	O
Republic	O
of	O
Korea	O
.	O
Wonju	O
26426	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
48108	O
,	O
Republic	O
of	O
Korea	O
.	O
Changwon	O
51353	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
46033	O
,	O
Republic	O
of	O
Korea	O
.	O
Jinju	O
52727	O
,	O
Republic	O
of	O
Korea	O
.	O
Incheon	O
21565	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
49267	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
49241	O
,	O
Republic	O
of	O
Korea	O
.	O

Phase	B-study_type
II	I-study_type
study	I-study_type
of	O
R	O
-	O
CVP	O
followed	O
by	O
rituximab	B-arm_description
maintenance	I-arm_description
therapy	I-arm_description
for	O
patients	O
with	O
advanced	O
marginal	O
zone	O
lymphoma	O
:	O
consortium	O
for	O
improving	O
survival	O
of	O
lymphoma	O
(	O
CISL	O
)	O
study	O

0000	O
-	O
0002	O
-	O
8321	O
-	O
4113	O
JinSeokKim	B-authors
SeokJinKim	B-authors
DokHyunYoon	B-authors
Deok	B-authors
-	I-authors
HwanYang	I-authors
WonSikLee	B-authors
HyoJungKim	B-authors
Ho	B-authors
-	I-authors
YoungYhim	I-authors
SeongHyunJeong	B-authors
JongHo	B-authors
Won	I-authors
SueeLee	B-authors
HyunJee	B-authors
Kong	I-authors
Sung	B-authors
-	I-authors
NamLim	I-authors
JunHo	B-authors
Ji13	I-authors
KyungAKwon	B-authors
Gyeong	B-authors
-	I-authors
WonLee	I-authors
JaeHoonLee	B-authors
SupHo	B-authors
Lee	I-authors
Ho	B-authors
-	I-authors
JinShin	I-authors
CheolwonSuh	B-authors
csuh@amc.seoul.kr	O

Songpa	O
-	O
gu	O
,	O
Seoul	O
05505	O
,	O
Republic	O
of	O
Korea	O
Busan	O
49201	O
,	O
Republic	O
of	O
Korea	O
.	O
Seoul	O
06351	O
,	O
Republic	O
of	O
Korea	O
.	O
Seoul	O
03722	O
,	O
Republic	O
of	O
Korea	O
.	O
Songpa	O
-	O
gu	O
,	O
Seoul	O
05505	O
,	O
Republic	O
of	O
Korea	O
.	O
Hwasun	O
58128	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
04511	O
,	O
Republic	O
of	O
Korea	O
.	O
Anyang	O
14068	O
,	O
Republic	O
of	O
Korea	O
.	O
Jeonju	O
54907	O
,	O
Republic	O
of	O
Korea	O
.	O
Suwon	O
16499	O
,	O
Republic	O
of	O
Korea	O
.	O
Seoul	O
04401	O
,	O
Republic	O
of	O
Korea	O
.	O
Wonju	O
26426	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
48108	O
,	O
Republic	O
of	O
Korea	O
.	O
Changwon	O
51353	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
46033	O
,	O
Republic	O
of	O
Korea	O
.	O
Jinju	O
52727	O
,	O
Republic	O
of	O
Korea	O
.	O
Incheon	O
21565	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
49267	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
49241	O
,	O
Republic	O
of	O
Korea	O
.	O

Phase	B-study_type
II	I-study_type
study	I-study_type
of	O
R	O
-	O
CVP	O
followed	O
by	O
rituximab	B-arm_description
maintenance	I-arm_description
therapy	I-arm_description
for	O
patients	O
with	O
advanced	O
marginal	O
zone	O
lymphoma	O
:	O
consortium	O
for	O
improving	O
survival	O
of	O
lymphoma	O
(	O
CISL	O
)	O
study	O

0000	O
-	O
0002	O
-	O
8321	O
-	O
4113	O
JinSeokKim	B-authors
SeokJinKim	B-authors
DokHyunYoon	B-authors
Deok	B-authors
-	I-authors
HwanYang	I-authors
WonSikLee	B-authors
HyoJungKim	B-authors
Ho	B-authors
-	I-authors
YoungYhim	I-authors
SeongHyunJeong	B-authors
JongHo	B-authors
Won	I-authors
SueeLee	B-authors
HyunJee	B-authors
Kong	I-authors
Sung	B-authors
-	I-authors
NamLim	I-authors
JunHo	B-authors
Ji13	I-authors
KyungAKwon	B-authors
Gyeong	B-authors
-	I-authors
WonLee	I-authors
JaeHoonLee	B-authors
SupHo	B-authors
Lee	I-authors
Ho	B-authors
-	I-authors
JinShin	I-authors
CheolwonSuh	B-authors
csuh@amc.seoul.kr	O

Songpa	O
-	O
gu	O
,	O
Seoul	O
05505	O
,	O
Republic	O
of	O
Korea	O
Busan	O
49201	O
,	O
Republic	O
of	O
Korea	O
.	O
Seoul	O
06351	O
,	O
Republic	O
of	O
Korea	O
.	O
Seoul	O
03722	O
,	O
Republic	O
of	O
Korea	O
.	O
Songpa	O
-	O
gu	O
,	O
Seoul	O
05505	O
,	O
Republic	O
of	O
Korea	O
.	O
Hwasun	O
58128	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
04511	O
,	O
Republic	O
of	O
Korea	O
.	O
Anyang	O
14068	O
,	O
Republic	O
of	O
Korea	O
.	O
Jeonju	O
54907	O
,	O
Republic	O
of	O
Korea	O
.	O
Suwon	O
16499	O
,	O
Republic	O
of	O
Korea	O
.	O
Seoul	O
04401	O
,	O
Republic	O
of	O
Korea	O
.	O
Wonju	O
26426	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
48108	O
,	O
Republic	O
of	O
Korea	O
.	O
Changwon	O
51353	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
46033	O
,	O
Republic	O
of	O
Korea	O
.	O
Jinju	O
52727	O
,	O
Republic	O
of	O
Korea	O
.	O
Incheon	O
21565	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
49267	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
49241	O
,	O
Republic	O
of	O
Korea	O
.	O

Phase	B-study_type
II	I-study_type
study	I-study_type
of	O
R	O
-	O
CVP	O
followed	O
by	O
rituximab	B-arm_description
maintenance	I-arm_description
therapy	I-arm_description
for	O
patients	O
with	O
advanced	O
marginal	O
zone	O
lymphoma	O
:	O
consortium	O
for	O
improving	O
survival	O
of	O
lymphoma	O
(	O
CISL	O
)	O
study	O
SungYongOh	B-authors

0000	O
-	O
0002	O
-	O
8321	O
-	O
4113	O
WonSeogKim	B-authors
Won	B-authors
Seog	I-authors
Kim	I-authors
0000	O
-	O
0002	O
-	O
8321	O
-	O
4113	O
JinSeokKim	B-authors
JinSeokKim	B-authors
Jin	B-authors
Seok	I-authors
Kim	I-authors
SeokJinKim	B-authors
SeokJinKim	B-authors
Seok	B-authors
Jin	I-authors
Kim	I-authors
DokHyunYoon	B-authors
DokHyunYoon	B-authors
Dok	B-authors
Hyun	I-authors
Yoon	I-authors
Deok	B-authors
-	I-authors
HwanYang	I-authors
Deok	B-authors
-	I-authors
HwanYang	I-authors
Deok	B-authors
-	I-authors
Hwan	I-authors
Yang	I-authors
WonSikLee	B-authors
WonSikLee	B-authors
Won	B-authors
Sik	I-authors
Lee	I-authors
HyoJungKim	B-authors
HyoJungKim	B-authors
Hyo	B-authors
Jung	I-authors
Kim	I-authors
Ho	B-authors
-	I-authors
YoungYhim	I-authors
Ho	B-authors
-	I-authors
YoungYhim	I-authors
Ho	B-authors
-	I-authors
Young	I-authors
Yhim	I-authors
SeongHyunJeong	B-authors
SeongHyunJeong	B-authors
Seong	B-authors
Hyun	I-authors
Jeong	I-authors
JongHo	B-authors
Won	I-authors
JongHo	B-authors
Won	I-authors
Jong	B-authors
Ho	I-authors
Won	I-authors
SueeLee	B-authors
SueeLee	B-authors
Suee	B-authors
Lee	I-authors
HyunJee	B-authors
HyunJee	B-authors
Hyun	B-authors
Jee	I-authors
Kong	B-authors
Kong	B-authors
Kong	B-authors
Sung	B-authors
-	I-authors
NamLim	I-authors
Sung	B-authors
-	I-authors
NamLim	I-authors
Sung	B-authors
-	I-authors
Nam	I-authors
Lim	I-authors
JunHo	B-authors
JunHo	B-authors
Jun	B-authors
Ho	I-authors
Ji13	B-authors
Ji13	B-authors
Ji	B-authors
13	O
KyungAKwon	B-authors
KyungAKwon	B-authors
Kyung	B-authors
A	I-authors
Kwon	I-authors
Gyeong	B-authors
-	I-authors
WonLee	I-authors
Gyeong	B-authors
-	I-authors
WonLee	I-authors
Gyeong	B-authors
-	I-authors
Won	I-authors
Lee	I-authors
JaeHoonLee	B-authors
JaeHoonLee	B-authors
Jae	B-authors
Hoon	I-authors
Lee	I-authors
SupHo	B-authors
SupHo	B-authors
Sup	B-authors
Ho	I-authors
Lee	B-authors
Lee	B-authors
Lee	B-authors
Ho	B-authors
-	I-authors
JinShin	I-authors
Ho	O
-	O
JinShin	O
Ho	B-authors
-	I-authors
Jin	I-authors
Shin	I-authors
CheolwonSuh	B-authors

Songpa	O
-	O
gu	O
,	O
Seoul	O
05505	O
,	O
Republic	O
of	O
Korea	O
Busan	O
49201	O
,	O
Republic	O
of	O
Korea	O
.	O
Seoul	O
06351	O
,	O
Republic	O
of	O
Korea	O
.	O
Seoul	O
03722	O
,	O
Republic	O
of	O
Korea	O
.	O
Songpa	O
-	O
gu	O
,	O
Seoul	O
05505	O
,	O
Republic	O
of	O
Korea	O
.	O
Hwasun	O
58128	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
04511	O
,	O
Republic	O
of	O
Korea	O
.	O
Anyang	O
14068	O
,	O
Republic	O
of	O
Korea	O
.	O
Jeonju	O
54907	O
,	O
Republic	O
of	O
Korea	O
.	O
Suwon	O
16499	O
,	O
Republic	O
of	O
Korea	O
.	O
Seoul	O
04401	O
,	O
Republic	O
of	O
Korea	O
.	O
Wonju	O
26426	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
48108	O
,	O
Republic	O
of	O
Korea	O
.	O
Changwon	O
51353	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
46033	O
,	O
Republic	O
of	O
Korea	O
.	O
Jinju	O
52727	O
,	O
Republic	O
of	O
Korea	O
.	O
Incheon	O
21565	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
49267	O
,	O
Republic	O
of	O
Korea	O
.	O
Busan	O
49241	O
,	O
Republic	O
of	O
Korea	O
.	O
4	O
Department	O
of	O
Oncology	O
,	O
Asan	O
Medical	O
Center	O
,	O
University	O
of	O
Ulsan	O
College	O
of	O
Medicine	O
,	O

Marginal	O
zone	O
lymphoma	O
(	O
MZL	O
)	O
is	O
a	O
B	O
cell	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
(	O
NHL	O
)	O
that	O
accounts	O
for	O
approximately	O
5%-17	O
%	O
of	O
all	O
NHL	O
in	O
adults	O
[	O
1	O
]	O
.	O
In	O
Korea	O
,	O
MZL	O
is	O
the	O
second	O
most	O
frequent	O
histological	O
NHL	O
subtype	O
after	O
diffuse	O
large	O
B	O
-	O
cell	O
lymphoma	O
,	O
constituting	O
one	O
-	O
fifth	O
of	O
all	O
NHL	O
cases	O
[	O
2	O
]	O
.	O
The	O
three	O
major	O
subtypes	O
of	O
MZL	O
defined	O
by	O
the	O
World	O
Health	O
Organization	O
(	O
WHO)-are	O
splenic	O
MZL	O
,	O
mucosa	O
-	O
associated	O
lymphoid	O
tissue	O
(	O
MALT	O
)	O
MZL	O
,	O
and	O
nodal	O
MZL	O
[	O
3,4	O
]	O
,	O
which	O
are	O
determined	O
by	O
the	O
anatomical	O
location	O
of	O
disease	O
-	O
initiating	O
B	O
-	O
cells	O
[	O
5	O
]	O
.	O
MALT	O
is	O
the	O
most	O
common	O
MZL	O
subtype	O
,	O
with	O
an	O
estimated	O
5-year	O
overall	O
survival	O
(	O
OS	O
)	O
and	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
>	O
90	O
%	O
and	O
70	O
%	O
while	O
nodal	O
MZL	O
has	O
been	O
associated	O
with	O
most	O
frequent	O
relapse	O
cases	O
[	O
2,[6][7][8	O
]	O
.	O
Overall	O
,	O
MZL	O
is	O
characterized	O
by	O
an	O
indolent	O
clinical	O
course	O
[	O
5	O
]	O
,	O
yet	O
remission	O
is	O
often	O
followed	O
by	O
multiple	O
relapses	O
[	O
9,10	O
]	O
,	O
highlighting	O
the	O
need	O
for	O
tolerable	O
maintenance	O
treatments	O
that	O
can	O
extend	O
the	O
remission	O
periods	O
induced	O
by	O
first	O
-	O
line	O
therapies	O
.	O

In	O
B	O
-	O
cell	O
malignancies	O
,	O
rituximab	O
(	O
Mabthera	O
®	O
;	O
Roche	O
,	O
Basel	O
,	O
Switzerland	O
)	O
was	O
the	O
first	O
targeted	O
therapy	O
drug	O
which	O
caused	O
a	O
paradigm	O
shift	O
in	O
disease	O
treatment	O
[	O
11	O
]	O
.	O
Rituximab	O
is	O
a	O
chimeric	O
,	O
monoclonal	O
antibody	O
targeting	O
CD20	O
,	O
a	O
cell	O
surface	O
antigen	O
expressed	O
during	O
most	O
stages	O
of	O
B	O
-	O
cell	O
development	O
[	O
12	O
]	O
,	O
and	O
is	O
found	O
on	O
95	O
%	O
of	O
B	O
-	O
cell	O
lymphoma	O
cells	O
[	O
13	O
]	O
.	O
The	O
clinical	O
efficacy	O
of	O
rituximab	O
was	O
first	O
demonstrated	O
in	O
follicular	O
lymphoma	O
(	O
FL	O
)	O
[	O
14,15	O
]	O
and	O
it	O
has	O
since	O
been	O
prescribed	O
for	O
other	O
subtypes	O
of	O
NHL	O
,	O
including	O
MZL	O
,	O
with	O
promising	O
results	O
[	O
16][17][18][19][20][21][22][23][24	O
]	O
.	O
In	O
this	O
study	O
,	O
we	O
evaluated	O
rituximab	B-arm_description
as	O
a	O
candidate	O
maintenance	O
therapy	O
in	O
patients	O
with	O
advanced	O
MZL	O
.	O

Despite	O
the	O
improved	O
response	O
and	O
progression	O
or	O
event	O
-	O
free	O
survival	O
rates	O
achieved	O
with	O
first	O
-	O
line	O
rituximab	O
-	O
containing	O
regimens	O
,	O
relapses	O
still	O
persist	O
once	O
the	O
treatment	O
is	O
completed	O
[	O
16][17][18][19][20][21][22][23][24	O
]	O
.	O
Typically	O
,	O
patients	O
suffer	O
multiple	O
relapses	O
,	O
and	O
subsequent	O
lines	O
of	O
therapy	O
for	O
MZL	O
patients	O
achieve	O
progressively	O
shorter	O
responses	O
[	O
9	O
]	O
,	O
therefore	O
,	O
extending	O
the	O
period	O
of	O
remission	O
for	O
MZL	O
patients	O
remains	O
an	O
essential	O
goal	O
.	O
One	O
potential	O
strategy	O
is	O
the	O
use	O
of	O
maintenance	O
therapy	O
once	O
a	O
response	O
has	O
been	O
achieved	O
with	O
first	O
-	O
line	O
therapy	O
.	O
Several	O
NHL	O
studies	O
have	O
previously	O
evaluated	O
rituximab	O
as	O
a	O
maintenance	O
agent	O
[	O
14,15,[28][29][30][31	O
]	O
.	O
FL	O
patients	O
who	O
receive	O
rituximab	O
-	O
maintenance	O
therapy	O
after	O
responding	O
to	O
first	O
-	O
line	O
rituximab	O
and	O
chemotherapy	O
experience	O
significantly	O
longer	O
PFS	O
compared	O
to	O
those	O
receiving	O
standard	O
treatment	O
[	O
14,15	O
]	O
.	O
Similar	O
results	O
were	O
reported	O
for	O
the	O
randomized	O
phase	O
III	O
primary	O
rituximab	O
and	O
maintenance	O
(	O
PRIMA	O
)	O
trial	O
,	O
in	O
which	O
2	O
years	O
of	O
rituximab	O
-	O
maintenance	O
therapy	O
significantly	O
improved	O
the	O
6-year	O
PFS	O
in	O
FL	O
patients	O
who	O
responded	O
to	O
first	O
-	O
line	O
rituximab	O
and	O
chemotherapy	O
combination	O
treatment	O
,	O
compared	O
to	O
patients	O
on	O
standard	O
therapy	O
[	O
R	O
-	O
CVP	O
or	O
R	O
-	O
CHOP	O
(	O
rituximab	O
,	O
cyclophosphamide	O
,	O
doxorubicin	O
,	O
vincristine	O
,	O
and	O
prednisolone	O
)	O
]	O
alone	O
[	O
28,29	O
]	O
.	O

Rituximab	O
-	O
maintenance	O
therapy	O
following	O
first	O
-	O
line	O
R	O
-	O
CVP	O
demonstrated	O
good	O
PFS	B-arm_efficacy_metric
in	O
patients	O
with	O
stage	O
III	O
-	O
IV	O
MZL	O
,	O
in	O
addition	O
to	O
a	O
favorable	O
toxicity	O
profile	O
.	O

The	O
studies	O
described	O
above	O
indicate	O
that	O
adding	O
rituximab	O
-	O
maintenance	O
therapy	O
to	O
a	O
rituximab	B-arm_description
-	O
based	O
immunochemotherapeutic	O
regimen	O
may	O
be	O
an	O
effective	O
strategy	O
for	O
extending	O
remission	O
in	O
patients	O
with	O
advanced	O
MZL	O
.	O
Here	O
we	O
report	O
the	O
results	O
of	O
a	O
phase	B-study_type
II	I-study_type
study	I-study_type
evaluating	O
the	O
effect	O
of	O
rituximab	B-arm_description
-	O
maintenance	O
treatment	O
following	O
R	O
-	O
CVP	O
as	O
a	O
first	O
-	O
line	O
therapy	O
on	O
the	O
survival	O
of	O
MZL	O
patients	O
.	O

This	O
was	O
a	O
multicenter	B-study_type
,	I-study_type
open	I-study_type
-	I-study_type
label	I-study_type
,	I-study_type
non	I-study_type
-	I-study_type
comparative	I-study_type
phase	I-study_type
II	I-study_type
study	I-study_type
conducted	O
in	O
medical	O
centers	O
across	O
South	O
Korea	O
(	O
ClinicalTrials.gov	O
identifier	O
NCT01213095	O
)	O
.	O
Patients	O
aged	O
≥	O
20	O
years	O
with	O
histologically	O
confirmed	O
,	O
Ann	O
Arbor	O
stage	O
III	O
-	O
IV	O
,	O
CD20-positive	O
MZL	O
were	O
eligible	O
for	O
this	O
study	O
.	O
The	O
patients	O
who	O
had	O
achieved	O
CR	O
,	O
partial	O
response	O
(	O
PR	O
)	O
,	O
or	O
stable	O
disease	O
(	O
SD	O
)	O
after	O
6	O
or	O
8	O
cycles	O
of	O
first	O
-	O
line	O
R	O
-	O
CVP	O
combination	O
therapy	O
,	O
as	O
defined	O
by	O
the	O
revised	O
International	O
Working	O
Group	O
(	O
IWG	O
)	O
response	O
criteria	O
for	O
malignant	O
lymphoma	O
were	O
enrolled	O
to	O
the	O
R	O
-	O
maintenance	O
clinical	O
trial	O
[	O
32	O
]	O
.	O

Enrolment	O
was	O
possible	O
even	O
without	O
symptom	O
for	O
first	O
-	O
line	O
treatment	O
with	O
R	O
-	O
CVP	O
.	O
Other	O
eligibility	O
criteria	O
were	O
presence	O
of	O
at	O
least	O
one	O
bi	O
-	O
dimensionally	O
measurable	O
lesion	O
(	O
≥	O
2	O
cm	O
by	O
conventional	O
computed	O
tomography	O
[	O
CT	O
]	O
,	O
≥	O
1	O
cm	O
by	O
spiral	O
CT	O
,	O
≥	O
2	O
cm	O
skin	O
lesion	O
,	O
or	O
≥	O
2	O
cm	O
on	O
physical	O
examination	O
)	O
at	O
first	O
line	O
R	O
-	O
CVP	O
treatment	O
;	O
had	O
an	O
Eastern	O
Clinical	O
Oncology	O
Group	O
(	O
ECOG	O
)	O
performance	O
status	O
(	O
PS	O
)	O
score	O
≤	O
2	O
;	O
and	O
adequate	O
renal	O
,	O
liver	O
and	O
bone	O
marrow	O
(	O
BM	O
)	O
functions	O
at	O
baseline	O
of	O
R	O
-	O
maintenance	O
enrollment	O
.	O

Patients	O
who	O
had	O
received	O
prior	O
chemotherapy	O
or	O
radiotherapy	O
for	O
MZL	O
were	O
excluded	O
from	O
the	O
study	O
,	O
as	O
were	O
those	O
with	O
a	O
large	O
cell	O
component	O
>	O
10	O
%	O
,	O
central	O
nervous	O
system	O
involvement	O
,	O
or	O
previous	O
malignancy	O
in	O
the	O
past	O
5	O
years	O
with	O
the	O
exceptions	O
of	O
curatively	O
treated	O
non	O
-	O
melanoma	O
skin	O
cancer	O
,	O
in	O
situ	O
carcinoma	O
of	O
the	O
cervix	O
uteri	O
,	O
or	O
thyroid	O
cancer	O
with	O
completed	O
active	O
treatment	O
and	O
no	O
evidence	O
of	O
recurrence	O
over	O
a	O
period	O
of	O
1	O
year	O
.	O
Informed	O
consent	O
was	O
obtained	O
from	O
all	O
patients	O
for	O
their	O
participation	O
in	O
the	O
study	O
.	O
Informed	O
consent	O
and	O
patients	O
'	O
enrolment	O
were	O
acquired	O
after	O
the	O
first	O
line	O
R	O
-	O
CVP	O
treatment	O
.	O
Investigators	O
clearly	O
discussed	O
with	O
the	O
patients	O
for	O
their	O
treatment	O
option	O
including	O
"	O
watchful	O
wait	O
"	O
.	O
This	O
clinical	O
trial	O
obtained	O
informed	O
consents	O
for	O
R	O
-	O
maintenance	O
treatment	O
.	O
This	O
study	O
was	O
conducted	O
in	O
accordance	O
with	O
the	O
Declaration	O
of	O
Helsinki	O
and	O
International	O
Conference	O
on	O
Harmonisation	O
Good	O
Clinical	O
Practice	O
guidelines	O
.	O
The	O
study	O
design	O
was	O
reviewed	O
and	O
approved	O
by	O
the	O
relevant	O
independent	O
ethics	O
committees	O
for	O
each	O
investigational	O
site	O
.	O
All	O
authors	O
had	O
access	O
to	O
primary	O
clinical	O
trial	O
data	O
.	O

Prior	O
to	O
rituximab	B-arm_description
-	I-arm_description
maintenance	I-arm_description
therapy	I-arm_description
,	O
patients	O
received	O
6	O
-	O
8	O
cycles	O
of	O
first	O
-	O
line	O
R	O
-	O
CVP	O
therapy	O
.	O
Rituximab	O
(	O
Roche	O
Pharm	O
Co.	O
,	O
Ltd.	O
,	O
Basel	O
,	O
Switzerland	O
)	O
(	O
375	B-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
)	O
,	O
cyclophosphamide	O
(	O
Bukwang	O
Pharm	O
Co.	O
,	O
Ltd	O
,	O
Seoul	O
,	O
Korea	O
)	O
(	O
750	O
mg	O
/	O
m	O
2	O
)	O
,	O
and	O
vincristine	O
(	O
1.4	O
mg/	O
m	O
2	O
;	O
maximum	O
2	O
mg	O
)	O
were	O
administered	O
via	O
an	O
intravenous	O
infusion	O
on	O
day	O
1	O
of	O
each	O
3-week	O
cycle	O
,	O
while	O
oral	O
prednisolone	O
(	O
Yuhan	O
Corporation	O
Co.	O
,	O
Ltd	O
,	O
Seoul	O
,	O
Korea	O
)	O
(	O
100	O
mg	O
)	O
was	O
given	O
on	O
days	O
1	O
-	O
5	O
of	O
each	O
3-week	O
cycle	O
.	O
Screening	O
assessments	O
of	O
tumor	O
response	O
before	O
initiating	O
rituximab	B-arm_description
-	I-arm_description
maintenance	I-arm_description
were	O
performed	O
on	B-arm_dosage
day	I-arm_dosage
21	I-arm_dosage
of	I-arm_dosage
the	I-arm_dosage
final	I-arm_dosage
R	I-arm_dosage
-	I-arm_dosage
CVP	I-arm_dosage
cycle	I-arm_dosage
,	I-arm_dosage
and	I-arm_dosage
within	I-arm_dosage
the	I-arm_dosage
14	I-arm_dosage
days	I-arm_dosage
prior	I-arm_dosage
to	I-arm_dosage
the	I-arm_dosage
first	I-arm_dosage
dose	I-arm_dosage
of	O
rituximab	B-arm_description
-	I-arm_description
maintenance	I-arm_description
treatment	O
.	O

Rituximab	B-arm_description
-	I-arm_description
maintenance	I-arm_description
therapy	I-arm_description
was	O
administered	O
intravenously	B-arm_dosage
at	I-arm_dosage
a	I-arm_dosage
dose	I-arm_dosage
of	I-arm_dosage
375	I-arm_dosage
mg	I-arm_dosage
/	I-arm_dosage
m	I-arm_dosage
2	I-arm_dosage
every	I-arm_dosage
8	I-arm_dosage
weeks	I-arm_dosage
for	I-arm_dosage
up	I-arm_dosage
to	I-arm_dosage
12	I-arm_dosage
cycles	I-arm_dosage
.	O
To	O
enhance	O
infusion	O
safety	O
,	O
infusion	O
rates	O
and	O
premedication	O
were	O
administered	O
according	O
to	O
the	O
rituximab	O
's	O
prescribing	O
information	O
[	O
33	O
]	O
.	O
Tumor	O
responses	O
were	O
assessed	O
according	O
to	O
the	O
IWG	O
criteria	O
[	O
32	O
]	O
at	O
screening	O
and	O
following	O
every	O
two	O
cycles	O
of	O
rituximab	O
-	O
maintenance	O
therapy	O
,	O
or	O
when	O
disease	O
progression	O
was	O
suspected	O
.	O
Evaluation	O
of	O
response	O
to	O
therapy	O
included	O
physical	O
examination	O
,	O
serum	O
lactate	O
dehydrogenase	O
(	O
LDH	O
)	O
,	O
CT	O
or	O
magnetic	O
resonance	O
imaging	O
of	O
initially	O
involved	O
sites	O
,	O
and	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
or	O
PET	O
-	O
CT	O
.	O
In	O
cases	O
of	O
initial	O
BM	O
involvement	O
,	O
bilateral	O
BM	O
aspiration	O
and	O
biopsies	O
were	O
performed	O
after	O
chemotherapy	O
completion	O
to	O
confirm	O
CR	O
.	O

Adverse	O
events	O
(	O
AEs	O
)	O
were	O
graded	O
according	O
to	O
the	O
National	O
Cancer	O
Institute	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
(	O
NCI	O
-	O
CTCAE	O
,	O
Version	O
4.03	O
)	O
.	O
Safety	O
monitoring	O
continued	O
up	O
to	O
30	O
days	O
after	O
the	O
final	O
cycle	O
of	O
rituximab	O
-	O
maintenance	O
.	O
Follow	O
-	O
up	O
was	O
continued	O
for	O
3	O
years	O
after	O
completing	O
the	O
study	O
treatment	O
,	O
and	O
the	O
tumors	O
were	O
assessed	O
in	O
imaging	O
studies	O
performed	O
every	O
6	O
months	O
until	O
disease	O
progression	O
was	O
detected	O
,	O
at	O
which	O
point	O
information	O
on	O
survival	O
and	O
new	O
lymphoma	O
treatment	O
were	O
updated	O
every	O
6	O
months	O
until	O
death	O
.	O

The	O
primary	O
endpoint	O
was	O
3-year	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
,	O
defined	O
the	O
length	O
of	O
time	O
during	O
and	O
after	O
the	O
R	O
-	O
CVP	O
treatment	O
of	O
MZL	O
that	O
a	O
patient	O
lives	O
with	O
the	O
disease	O
but	O
it	O
does	O
not	O
get	O
worse	O
.	O
Secondary	O
endpoints	O
were	O
(	O
1	O
)	O
overall	O
survival	O
(	O
OS	O
)	O
,	O
defined	O
from	O
the	O
length	O
of	O
time	O
of	O
R	O
-	O
CVP	O
treatment	O
commencement	O
until	O
death	O
due	O
to	O
any	O
cause	O
or	O
the	O
date	O
of	O
the	O
last	O
follow	O
-	O
up	O
,	O
and	O
(	O
2	O
)	O
treatment	O
safety	O
.	O

This	O
trial	O
was	O
designed	O
according	O
to	O
the	O
Simon	O
"	O
optimal	O
"	O
design	O
for	O
phase	O
II	O
trials	O
and	O
aimed	O
to	O
determine	O
whether	O
rituximab	B-arm_description
-	I-arm_description
maintenance	I-arm_description
following	O
R	O
-	O
CVP	O
could	O
improve	O
PFS	B-arm_efficacy_metric
[	O
33	O
]	O
.	O
Based	O
on	O
literature	O
analyses	O
[	O
7,24	O
]	O
,	O
the	O
baseline	O
3-year	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
rate	I-arm_efficacy_metric
was	O
expected	O
to	O
be	O
50	O
%	O
,	O
with	O
an	O
anticipated	O
treatment	O
difference	O
of	O
20	O
%	O
.	O
Assuming	O
a	O
drop	O
-	O
out	O
rate	O
of	O
10	O
%	O
,	O
a	O
total	O
of	O
47	O
patients	O
were	O
required	O
to	O
achieve	O
a	O
power	O
of	O
80	O
%	O
to	O
detect	O
a	O
20	O
%	O
treatment	O
difference	O
with	O
an	O
alpha	O
of	O
0.05	O
.	O
PFS	B-arm_efficacy_metric
was	O
defined	O
as	O
the	O
time	O
R	O
-	O
CVP	O
treatment	O
started	O
to	O
the	O
first	O
recorded	O
incidence	O
of	O
relapse	O
,	O
disease	O
progression	O
,	O
death	O
due	O
to	O
any	O
cause	O
,	O
or	O
last	O
date	O
of	O
follow	O
up	O
for	O
the	O
enrolled	O
patients	O
who	O
did	O
not	O
progress	O
.	O

The	O
intent	O
-	O
to	O
-	O
treat	O
population	O
(	O
for	O
efficacy	O
analysis	O
)	O
and	O
safety	O
population	O
(	O
for	O
safety	O
analysis	O
)	O
both	O
included	O
enrolled	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
rituximab	B-arm_description
-	I-arm_description
maintenance	I-arm_description
therapy	O
.	O
Time	O
-	O
to	O
-	O
event	O
data	O
were	O
estimated	O
using	O
the	O
Kaplan	O
-	O
Meier	O
method	O
.	O
The	O
Cox	O
proportional	O
hazards	O
model	O
was	O
used	O
to	O
estimate	O
the	O
hazard	O
ratio	O
(	O
HR	O
)	O
and	O
the	O
corresponding	O
95	O
%	O
CI	O
with	O
regard	O
to	O
the	O
low	O
-	O
risk	O
group	O
.	O
All	O
reported	O
P	O
values	O
were	O
twosided	O
,	O
and	O
a	O
P	O
value	O
<	O
0.05	O
was	O
considered	O
significant	O
.	O
All	O
analyses	O
were	O
conducted	O
using	O
the	O
Statistical	O
Package	O
for	O
Social	O
Sciences	O
version	O
20.0	O
for	O
Windows	O
(	O
SPSS	O
Inc.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

A	O
total	O
of	O
47	O
patients	O
were	O
enrolled	O
into	O
this	O
trial	O
from	O
a	O
total	O
of	O
18	O
centers	O
,	O
of	O
whom	O
,	O
45	O
(	O
96	O
%	O
)	O
received	O
rituximab	B-arm_description
-	I-arm_description
maintenance	I-arm_description
treatment	O
.	O
One	O
(	O
2	O
%	O
)	O
patient	O
failed	O
screening	O
due	O
to	O
thyroid	O
cancer	O
,	O
and	O
one	O
(	O
2	O
%	O
)	O
patient	O
withdrew	O
consent	O
(	O
Fig	O
.	O
1	O
)	O
.	O
The	O
first	O
patient	O
of	O
the	O
trial	O
was	O
enrolled	O
on	O
October	O
19	O
,	O
2010	O
,	O
and	O
the	O
date	O
of	O
last	O
follow	O
-	O
up	O
was	O
on	O
February	O
4	O
,	O
2016	O
.	O
In	O
total	O
,	O
34	O
(	O
72	O
%	O
)	O
patients	O
completed	O
the	O
planned	O
12	O
cycles	O
of	O
rituximabmaintenance	B-arm_description
therapy	O
(	O
Fig	O
.	O
1	O
)	O
.	O
Six	O
(	O
13	O
%	O
)	O
patients	O
discontinued	O
due	O
to	O
progressive	O
disease	O
(	O
PD	O
)	O
,	O
while	O
two	O
(	O
4	O
%	O
)	O
discontinued	O
due	O
to	O
AEs	O
,	O
one	O
(	O
2	O
%	O
)	O
was	O
lost	O
to	O
follow	O
-	O
up	O
,	O
one	O
(	O
2	O
%	O
)	O
withdrew	O
consent	O
,	O
and	O
one	O
(	O
2	O
%	O
)	O
died	O
(	O
pneumonia	O
,	O
after	O
11	O
cycles	O
)	O
prior	O
to	O
the	O
rituximab	B-arm_description
-	I-arm_description
maintenance	I-arm_description
treatment	O
completion	O
.	O

Baseline	O
patient	O
demographics	O
and	O
disease	O
characteristics	O
are	O
summarized	O
in	O
Table	O
1	O
.	O
The	O
median	O
age	O
was	O
54	O
years	O
(	O
range	O
,	O
33	O
-	O
77	O
years	O
)	O
,	O
and	O
43	O
(	O
96	O
%	O
)	O
patients	O
had	O
an	O
ECOG	O
performance	O
score	O
≤	O
1	O
.	O
In	O
total	O
,	O
15	O
(	O
33	O
%	O
)	O
patients	O
had	O
nodal	O
MZL	O
and	O
30	O
(	O
67	O
%	O
)	O
had	O
MALT	O
MZL	O
.	O
Following	O
R	O
-	O
CVP	O
first	O
-	O
line	O
therapy	O
,	O
20	O
(	O
44	O
%	O
)	O
,	O
22	O
(	O
49	O
%	O
)	O
,	O
and	O
3	O
(	O
7	O
%	O
)	O
patients	O
achieved	O
CR	O
,	O
PR	O
,	O
and	O
SD	O
,	O
respectively	O
(	O
Table	O
1	O
)	O
.	O
The	O
number	O
of	O
patients	O
who	O
received	O
6	O
or	O
8	O
cycles	O
of	O
prior	O
R	O
-	O
CVP	O
therapy	O
were	O
10	O
(	O
22	O
%	O
)	O
and	O
35	O
(	O
78	O
%	O
)	O
,	O
respectively	O
(	O
Table	O
1	O
)	O
.	O

After	O
a	O
median	O
follow	O
-	O
up	O
of	O
38.2	O
months	O
,	O
the	O
3-year	B-arm_efficacy_metric
PFS	I-arm_efficacy_metric
rate	O
was	O
found	O
to	O
be	O
81	B-arm_efficacy_results
%	I-arm_efficacy_results
(	O
Fig	O
.	O
2	O
)	O
.	O
During	O
the	O
rituximab	B-arm_description
-	I-arm_description
maintenance	I-arm_description
therapy	O
,	O
6	O
PR	O
patients	O
and	O
1	O
SD	O
patient	O
achieved	O
CR	O
following	O
R	O
-	O
CVP	O
.	O
Univariate	O
analyses	O
showed	O
that	O
elevated	O
LDH	O
(	B-arm_efficacy_results
HR	I-arm_efficacy_results
6.819	I-arm_efficacy_results
;	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
1.885	I-arm_efficacy_results
-	I-arm_efficacy_results
24.667	I-arm_efficacy_results
;	I-arm_efficacy_results
P	I-arm_efficacy_results
=	I-arm_efficacy_results
0.003	I-arm_efficacy_results
)	I-arm_efficacy_results
and	O
the	O
presence	O
of	O
B	O
symptoms	O
(	B-arm_efficacy_results
HR	I-arm_efficacy_results
0.130	I-arm_efficacy_results
;	I-arm_efficacy_results
95	I-arm_efficacy_results
%	I-arm_efficacy_results
CI	I-arm_efficacy_results
0.034	I-arm_efficacy_results
-	I-arm_efficacy_results
0.500	I-arm_efficacy_results
;	I-arm_efficacy_results
P	I-arm_efficacy_results
=	I-arm_efficacy_results
0.003	I-arm_efficacy_results
)	I-arm_efficacy_results
to	O
be	O
significant	O
prognostic	O
factors	O
for	O
PFS	B-arm_efficacy_metric
following	O
rituximab	B-arm_description
-	I-arm_description
maintenance	I-arm_description
(	O
Table	O
2	O
)	O
.	O
MZL	O
subtype	O
was	O
not	O
a	O
significant	O
prognostic	O
factor	O
for	O
PFS	B-arm_efficacy_metric
,	O
nor	O
was	O
response	O
to	O
R	O
-	O
CVP	O
(	O
CR	O
vs.	O
<	O
CR	O
;	O
Table	O
2	O
)	O
.	O
After	O
a	O
median	O
follow	O
-	O
up	O
of	O
38.2	O
months	O
,	O
the	O
3-year	O
OS	O
rate	O
was	O
found	O
to	O
be	O
90	O
%	O
(	O
Fig	O
.	O
3	O
)	O
.	O

In	O
conclusion	O
,	O
this	O
single	B-study_type
-	I-study_type
arm	I-study_type
,	I-study_type
open	I-study_type
-	I-study_type
label	I-study_type
,	I-study_type
multicenter	I-study_type
phase	I-study_type
II	I-study_type
study	I-study_type
of	O
rituximab	B-arm_description
-	I-arm_description
maintenance	I-arm_description
following	O
firstline	O
R	O
-	O
CVP	O
therapy	O
demonstrated	O
good	O
PFS	B-arm_efficacy_metric
in	O
patients	O
with	O
advanced	O
-	O
stage	O
MZL	O
,	O
with	O
tolerable	O
toxicities	O
.	O